Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.64 |
| ▸ | RAB9A | P51151 | 10/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813210 | 0.95 | NPC1 (0.64) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6813517 | 0.90 | NPC1 (0.55) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL11575815 | 0.87 | NPC1 (0.53) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL17512414 | 0.87 | RAB9A (0.57) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6813395 | 0.86 | HDAC8 (0.64) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL17512366 | 0.86 | MAPT (0.59) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6812535 | 0.85 | EPHX1 (0.63) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL17512374 | 0.85 | NPC1 (0.61) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL11318579 | 0.84 | NPC1 (0.58) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL17512369 | 0.83 | RAB9A (0.56) | NPC1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090060905-A1 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity | GENFIT (FR) | 2009-03-05 | — | — | US | claimed |
| EP-1666883-A1 | Diagnostic and monitoring methods for bone loss | F. Hoffmann-La Roche AG (CH) | 2006-06-07 | — | — | EP | claimed |
| EP-1476153-A2 | METHOD OF TREATING AND PREVENTING BONE LOSS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | claimed |
| WO-2003066048-A2 | USE OF 15-LIPOXYGENASE INHIBITORS FOR TREATING AND PREVENTING BONE LOSS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | claimed |
| US-6528528-B2 | Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | claimed |
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | claimed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2016029136-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G | NORTHWESTERN UNIVERSITY (US) | 2016-02-25 | — | — | WO | disclosed |
| US-20160052870-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS | NORTHWESTERN UNIVERSITY (US) | 2016-02-25 | — | — | US | disclosed |
| US-8048900-B2 | Use of 15-lipoxygenase inhibitors for treating obesity | GENFIT S.A. (FR) | 2011-11-01 | — | — | US | disclosed |
| US-20090060905-A1 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity | GENFIT (FR) | 2009-03-05 | — | — | US | disclosed |
| WO-2003066048-A2 | USE OF 15-LIPOXYGENASE INHIBITORS FOR TREATING AND PREVENTING BONE LOSS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
| US-6528528-B2 | Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | disclosed |
| US-6268387-B1 | INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. | WARNER-LAMBERT COMPANY | 2001-07-31 | — | — | US | disclosed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060905-A1 | Use of 15-Lipoxygenase Inhibitors for Treating Obesity | ALOX15, ALOX15B, ALOX12 | NPC1 2376/4885RAB9A 3958/4885MAPT 4764/4885 |
| US-20160052870-A1 | 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS | L3MBTL3, AFG3L2, AMPD3 | NPC1 2573/4885RAB9A 3095/4885MAPT 4742/4885 |
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | TPMT, CTH, CBS | NPC1 230/4885RAB9A 4084/4885MAPT 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.